share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/12 13:23
Moomoo AI 已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.
生物製藥公司Apollomics Inc. 對美國證券交易委員會關於其在中國業務的評論做出了回應。正如美國證券交易委員會於2024年4月1日提交的F-3表格註冊聲明中所述，美國證券交易委員會公司財務部已要求澄清Apollomics在中國的業務範圍。在2024年4月12日的一封信中，Apollomics澄清說，其大部分業務不是在中國進行的，而是通過其位於加利福尼亞的全資子公司進行的，其業務總部和管理團隊設在美國。該公司還強調，其大部分研發，包括臨床試驗，都是在中國境外進行的，特別是在美國和澳大利亞。Apollomics堅持認爲，其研發工作和支出中只有不到20％與其在香港和中國大陸的業務有關，該公司在香港和中國大陸有兩家全資子公司。該公司進一步表示，其大部分現金和支出都是在中國境外持有和產生的，這進一步表明其主要業務並不以中國爲中心。
生物製藥公司Apollomics Inc. 對美國證券交易委員會關於其在中國業務的評論做出了回應。正如美國證券交易委員會於2024年4月1日提交的F-3表格註冊聲明中所述，美國證券交易委員會公司財務部已要求澄清Apollomics在中國的業務範圍。在2024年4月12日的一封信中，Apollomics澄清說，其大部分業務不是在中國進行的，而是通過其位於加利福尼亞的全資子公司進行的，其業務總部和管理團隊設在美國。該公司還強調，其大部分研發，包括臨床試驗，都是在中國境外進行的，特別是在美國和澳大利亞。Apollomics堅持認爲，其研發工作和支出中只有不到20％與其在香港和中國大陸的業務有關，該公司在香港和中國大陸有兩家全資子公司。該公司進一步表示，其大部分現金和支出都是在中國境外持有和產生的，這進一步表明其主要業務並不以中國爲中心。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息